Post-Hoc: Why we tracked pharma’s private jet flights to DCnews2025-10-23T17:02:11+00:00October 23rd, 2025|Endpoints News|
Merck KGaA to end API work at Irish plant after ‘strategic portfolio review’news2025-10-23T16:24:04+00:00October 23rd, 2025|Endpoints News|
Lonza expects more CDMO contracts; Galderma’s $650M US commitmentnews2025-10-23T15:55:08+00:00October 23rd, 2025|Endpoints News|
Mikael Dolsten, Craig Crews team up for new molecular glue biotechnews2025-10-23T15:27:01+00:00October 23rd, 2025|Endpoints News|
Icon warns of macro environment headwinds as Medpace maintains revenue momentumnews2025-10-23T15:18:35+00:00October 23rd, 2025|Endpoints News|
Tango to advance pancreatic cancer drug into Phase 3, raises $225Mnews2025-10-23T15:06:00+00:00October 23rd, 2025|Endpoints News|
Ventyx’s stock soars on cardiovascular data for NLRP3 drugnews2025-10-23T14:31:10+00:00October 23rd, 2025|Endpoints News|
Are recent strides in neurology R&D enough to make it a hot M&A target?news2025-10-23T14:00:48+00:00October 23rd, 2025|Endpoints News|
Drugmakers push to break ground after Trump’s 100% tariff threatnews2025-10-23T13:27:43+00:00October 23rd, 2025|Endpoints News|
Drug launch prices spiked from 2022 to 2024, new ICER report findsnews2025-10-23T12:00:38+00:00October 23rd, 2025|Endpoints News|
